These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

573 related items for PubMed ID: 17457827

  • 1. Cost-effectiveness of influenza vaccination in working-age cancer patients.
    Avritscher EB, Cooksley CD, Geraci JM, Bekele BN, Cantor SB, Rolston KV, Elting LS.
    Cancer; 2007 Jun 01; 109(11):2357-64. PubMed ID: 17457827
    [Abstract] [Full Text] [Related]

  • 2. Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis.
    Rothberg MB, Rose DN.
    Am J Med; 2005 Jan 01; 118(1):68-77. PubMed ID: 15639212
    [Abstract] [Full Text] [Related]

  • 3. The cost effectiveness of influenza vaccination for adults aged 50 to 64 years: a model-based analysis for Spain.
    Aballéa S, De Juanes JR, Barbieri M, Martin M, Chancellor J, Oyagüez I, Verwee B, Largeron N.
    Vaccine; 2007 Sep 28; 25(39-40):6900-10. PubMed ID: 17764790
    [Abstract] [Full Text] [Related]

  • 4. The cost-effectiveness of a universal influenza vaccination program for adults aged 50-64 years in Australia.
    Newall AT, Scuffham PA, Kelly H, Harsley S, Macintyre CR.
    Vaccine; 2008 Apr 16; 26(17):2142-53. PubMed ID: 18343537
    [Abstract] [Full Text] [Related]

  • 5. Influenza vaccination health impact and cost effectiveness among adults aged 50 to 64 and 65 and older.
    Maciosek MV, Solberg LI, Coffield AB, Edwards NM, Goodman MJ.
    Am J Prev Med; 2006 Jul 16; 31(1):72-9. PubMed ID: 16777545
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24-59 months in the United States.
    Luce BR, Nichol KL, Belshe RB, Frick KD, Li SX, Boscoe A, Rousculp MD, Mahadevia PJ.
    Vaccine; 2008 Jun 02; 26(23):2841-8. PubMed ID: 18462851
    [Abstract] [Full Text] [Related]

  • 7. The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model.
    Aballéa S, Chancellor J, Martin M, Wutzler P, Carrat F, Gasparini R, Toniolo-Neto J, Drummond M, Weinstein M.
    Value Health; 2007 Jun 02; 10(2):98-116. PubMed ID: 17391419
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness of influenza vaccination of healthy children.
    Salo H, Kilpi T, Sintonen H, Linna M, Peltola V, Heikkinen T.
    Vaccine; 2006 Jun 05; 24(23):4934-41. PubMed ID: 16678945
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of a recommendation of universal mass vaccination for seasonal influenza in the United States.
    Clements KM, Chancellor J, Nichol K, DeLong K, Thompson D.
    Value Health; 2011 Jun 05; 14(6):800-11. PubMed ID: 21914499
    [Abstract] [Full Text] [Related]

  • 10. The cost-effectiveness of vaccinating pregnant women against seasonal influenza in England and Wales.
    Jit M, Cromer D, Baguelin M, Stowe J, Andrews N, Miller E.
    Vaccine; 2010 Dec 10; 29(1):115-22. PubMed ID: 21055501
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness analysis of influenza vaccination for people aged 65 and over in Japan.
    Hoshi SL, Kondo M, Honda Y, Okubo I.
    Vaccine; 2007 Aug 29; 25(35):6511-21. PubMed ID: 17681651
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness analysis of inactivated virosomal subunit influenza vaccination in children aged 3-14 years from the provider and societal perspectives.
    Navas E, Salleras L, Domínguez A, Ibáñez D, Prat A, Sentís J, Garrido P.
    Vaccine; 2007 Apr 20; 25(16):3233-9. PubMed ID: 17324489
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States.
    Shepard CW, Ortega-Sanchez IR, Scott RD, Rosenstein NE, ABCs Team.
    Pediatrics; 2005 May 20; 115(5):1220-32. PubMed ID: 15867028
    [Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness of influenza vaccination of people aged 50-64 years in Australia: results are inconclusive.
    Mogasale V, Barendregt J.
    Aust N Z J Public Health; 2011 Apr 20; 35(2):180-6. PubMed ID: 21463417
    [Abstract] [Full Text] [Related]

  • 15. Could a federal program to promote influenza vaccination among elders be cost-effective?
    Patel MS, Davis MM.
    Prev Med; 2006 Mar 20; 42(3):240-6. PubMed ID: 16480761
    [Abstract] [Full Text] [Related]

  • 16. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?
    Braithwaite RS, Meltzer DO, King JT, Leslie D, Roberts MS.
    Med Care; 2008 Apr 20; 46(4):349-56. PubMed ID: 18362813
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of universal influenza vaccination in a pregnant population.
    Roberts S, Hollier LM, Sheffield J, Laibl V, Wendel GD.
    Obstet Gynecol; 2006 Jun 20; 107(6):1323-9. PubMed ID: 16738159
    [Abstract] [Full Text] [Related]

  • 18. Oseltamivir for influenza postexposure prophylaxis: economic evaluation for children aged 1-12 years in the U.S.
    Talbird SE, Brogan AJ, Winiarski AP.
    Am J Prev Med; 2009 Nov 20; 37(5):381-8. PubMed ID: 19840692
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness analysis of influenza and pneumococcal vaccination for Hong Kong elderly in long-term care facilities.
    You JH, Wong WC, Ip M, Lee NL, Ho SC.
    J Epidemiol Community Health; 2009 Nov 20; 63(11):906-11. PubMed ID: 19608558
    [Abstract] [Full Text] [Related]

  • 20. Cost effectiveness of hepatitis B vaccination at HIV counseling and testing sites.
    Kim SY, Billah K, Lieu TA, Weinstein MC.
    Am J Prev Med; 2006 Jun 20; 30(6):498-506. PubMed ID: 16704944
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.